Gerald Post, DVM, MEM
Professor Adjunct of Comparative MedicineCards
About
Research
Publications
2023
Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy
Heinze C, Burgess K, Barber L, Rassnick K, Post G, Segaloff R, Bayle J. Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy. Veterinary And Comparative Oncology 2023, 22: 2-11. PMID: 37933436, PMCID: PMC11115191, DOI: 10.1111/vco.12940.Peer-Reviewed Original ResearchQuality of lifeAdverse eventsFecal scoreGastrointestinal adverse eventsC-reactive proteinClient-owned dogsMulticenter clinical trialChemoattractant protein-1Mast cell tumorsFrequency of signsSignificant differencesCancer treatment optionsImpact of dietTest dietsQOL parametersCare chemotherapyLaboratory parametersPrimary outcomeOncology patientsFatty acidsLarge trialsMulticentric lymphomaQOL improvementTreatment optionsCell tumors
2021
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadineThe Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effects
2020
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
Saba C, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post G, Thamm D. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Veterinary And Comparative Oncology 2020, 18: 763-769. PMID: 32346934, PMCID: PMC7754483, DOI: 10.1111/vco.12605.Peer-Reviewed Original ResearchConceptsLarge cell lymphomaCell lymphomaOverall median progression-free intervalMedian progression-free intervalAdverse event evaluationAdverse event profileMinute intravenous infusionProgression-free intervalProspective clinical trialsT-cell immunophenotypeOverall response rateSubstantial antitumour activityDrug-resistant relapseRelapsed subjectsSupportive treatmentUntreated dogsUntreated lymphomaConcurrent corticosteroidsDosage adjustmentPulmonary fibrosisEvent profileGastrointestinal originGroup criteriaIntravenous infusionInferior outcomesConcurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2018
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
Hendricks W, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery N, Washington M, Aldrich J, Neff M, Huentelman M, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent J. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLOS Genetics 2018, 14: e1007589. PMID: 30188888, PMCID: PMC6126841, DOI: 10.1371/journal.pgen.1007589.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell CycleCell ProliferationComparative Genomic HybridizationDNA Mutational AnalysisDog DiseasesDogsFemaleMaleMelanomaMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor-Like Protein Tyrosine Phosphatases, Class 3Signal TransductionSkin NeoplasmsTissue Array AnalysisConceptsLow point mutation ratePowerful comparative modelComparative genomic analysisCell cycle controlPoint mutation rateSingle nucleotide polymorphism arrayNucleotide polymorphism arrayWhole-genome sequencingArray comparative genomic hybridizationHuman melanomaComparative genomic hybridizationGenomic analysisRNA sequencingCycle controlGenome sequencingMutation rateGenomic landscapePolymorphism arrayCopy numberMutational landscapeMutational signaturesGenomic hybridizationRecurrent alterationsMulti-platform analysisMutationsExceptional responders in conservation
Post G, Geldmann J. Exceptional responders in conservation. Conservation Biology 2018, 32: 576-583. PMID: 28856730, DOI: 10.1111/cobi.13006.Peer-Reviewed Original Research
2017
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research 2017, 23: 2565-2574. PMID: 27815356, PMCID: PMC5418113, DOI: 10.1158/1078-0432.ccr-16-2152.Peer-Reviewed Original ResearchConceptsMast cell tumorsSpontaneous mast cell tumoursMast cell numbersMast cell degranulationCutaneous mast cell numberKIT phosphorylationCell degranulationOpen-label clinical studyBiochemical adverse eventsAcceptable safety profileMetastatic lymph nodesPharmacokinetics/pharmacodynamics profileFuture clinical evaluationClin Cancer ResCell numberDose-dependent mannerObjective responseAdverse eventsLymph nodesMCT patientsClinical effectsClinical toxicityClinical benefitHuman clinical applicationsSafety profileGeographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
Wilson‐Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary And Comparative Oncology 2017, 15: 1564-1571. PMID: 28419683, DOI: 10.1111/vco.12302.Peer-Reviewed Original ResearchConceptsProgression-free survivalFree survivalMultivariable Cox regression modelsShorter progression-free survivalSurvival of dogsCox regression modelNon-Hodgkin lymphomaCHOP chemotherapyChemotherapy protocolsReferral institutionMedical recordsUnivariate analysisDoxorubicin dosesCanine lymphomaVeterinary oncologyDoxorubicin treatmentGeographical differencesLymphomaDogsSignificant differencesImmunophenotypeSurvivalRegression modelsGeographic differencesUS regionsAlternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
Thamm D, Vail D, Post G, Fan T, Phillips B, Axiak‐Bechtel S, Elmslie R, Klein M, Ruslander D. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Journal Of Veterinary Internal Medicine 2017, 31: 872-878. PMID: 28370378, PMCID: PMC5435064, DOI: 10.1111/jvim.14700.Peer-Reviewed Original ResearchConceptsProgression-free intervalMulticentric lymphomaComplete responseOverall median progression-free intervalMedian progression-free intervalMulticenter prospective clinical trialSubstantial single-agent activityAdverse effect profileAssessment of remissionMost adverse eventsProspective clinical trialsSingle-agent activityLong-term outcomesOverall response rateCanine multicentric lymphomaDermatologic AEsHematologic AEsClinicopathological evaluationAdverse eventsChemotherapy combinationsCombination chemotherapyTreatment visitsUntreated lymphomaEffect profilePulmonary fibrosis